文献速递胸部肿瘤

水飞蓟宾增敏克唑替尼抑制ALK阳性非小细胞肺癌细胞的作用及机制

[Effect and mechanism of silibinin on the inhibition of ALK positive NSCLC cells by sensitizing crizotinib].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2017-01-01

研究水飞蓟宾联合克唑替尼对ALK阳性NSCLC细胞株H2228和H3122的协同抑制作用及机制。联合用药使克唑替尼对H2228和H3122细胞的IC50分别从(917.10±7.75)nmol/L降至(238.73±7.67)nmol/L、从(472.50±15.70)nmol/L降至(206.10±12.01)nmol/L(P<0.01),并明显抑制克隆形成、迁移和侵袭。裸鼠移植瘤模型中联合组肿瘤重量(4.58±1.07)g低于克唑替尼单药组(9.40±2.58)g(P<0.05)。

要点

  • 水飞蓟宾联合克唑替尼使H2228细胞IC50从(917.10±7.75)nmol/L降至(238.73±7.67)nmol/L(P<0.01)。
  • 水飞蓟宾联合克唑替尼使H3122细胞IC50从(472.50±15.70)nmol/L降至(206.10±12.01)nmol/L(P<0.01)。
  • 裸鼠移植瘤中联合组肿瘤重量(4.58±1.07)g低于克唑替尼单药组(9.40±2.58)g(P<0.05)。

核心结论

  • 水飞蓟宾可增强克唑替尼对ALK阳性NSCLC细胞的增殖抑制作用,其机制可能与两药联用能进一步降低ALK阳性NSCLC细胞的ALK活性,促进间质上皮转化(MET)的发生有关。

研究设计与样本

  • 体外研究:以单加水飞蓟宾、单加克唑替尼或两药联合作用于NSCLC细胞株H2228和H3122,采用MTT法、克隆形成实验、划痕实验、侵袭实验、免疫荧光实验和Western blot法检测。
  • 体内研究:将H2228细胞悬液注射入裸鼠皮下构建裸鼠移植瘤模型,观察移植瘤生长情况。

主要发现

  • 当水飞蓟宾浓度为100 μmol/L时,H2228和H3122细胞的存活率分别为(88.38±4.10)%和(72.27±3.62)%,对细胞的增殖活性影响较小。
  • 与单用克唑替尼比较,100 μmol/L水飞蓟宾联合克唑替尼使H2228细胞IC50从(917.10±7.75)nmol/L降至(238.73±7.67)nmol/L,H3122细胞IC50从(472.50±15.70)nmol/L降至(206.10±12.01)nmol/L(P<0.01)。
  • 与对照组H2228细胞比较,100 μmol/L水飞蓟宾组、400 nmol/L克唑替尼组、联合组克隆形成率分别为(83.34±2.72)%、(69.42±3.06)%和(27.32±1.42)%;与对照组H3122细胞比较,上述三组克隆形成率分别为(84.45±5.67)%、(45.02±5.83)%和(17.43±3.83)%;联合用药后H2228和H3122细胞克隆形成能力均明显下降(均P<0.01)。
  • 迁移和侵袭实验显示,水飞蓟宾与克唑替尼联用能明显抑制H2228细胞的迁移和侵袭(均P<0.01)。
  • Western blot显示,单用水飞蓟宾或联合克唑替尼48小时,H2228细胞E-Cadherin蛋白表达明显升高,p-ALK和Vimentin蛋白表达明显下降,ALK总蛋白表达无明显变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the synergistic effect of silibinin combined with crizotinib on anaplastic lymphoma kinase positive (ALK+ ) non-small cell lung cancer (NSCLC) cells and its mechanism. Methods: H2228 and H3122 cells were treated with silibinin, crizotinib alone or in combination. Cell proliferation was measured by 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay and colony formation assay. Migration or invasion ability was tested by wound healing assay or transwell assay, respectively. Expressions of E-Cadherin and vimentin protein were examined by immunofluorescence staining. The protein expressions of ALK, p-ALK, E-Cadherin and Vimentin were detected by western blotting.The anti-cancer effect of silibinin combined with crizotinib in vivo was determined by subcutaneously injecting 2×10(6) H2228 cells into immunodeficient nude mice. Results: The result of MTT assay showed that the cell viability of H2228 or H3122 treated with 100 μmol/L silibinin was (88.38±4.10)% or (72.27±3.62)%, respectively, marginally decreased compared with that of the control. The 50% inhibitory concentration (IC(50)) of H2228 cells treated with crizotinib alone or combined with 100 μmol/L silibinin was (917.10±7.75) nmol/L or (238.73±7.67) nmol/L, respectively. The IC(50) of H3122 cells treated with crizotinib alone or combined with 100 μmol/L silibinin was (472.50±15.70) nmol/L or (206.10±12.01) nmol/L, respectively. The IC(50s) of H2228 and H3122 cells were significantly decreased by combined treatment of crizotinib and silibinin compared to crizotinib treatment alone (P<0.01). When compared with the control group, colony forming ratios of H2228 cells were (83.34±2.72)% in 100 μmol/L silibinin treatment group, (69.42±3.06)% in 400 nmol/L crizotinib treatment group and (27.32±1.42)% in combined treatment group. When compared with the control group, colony forming ratios of H3122 cells were (84.45±5.67)% in 100 μmol/L silibinin treatment group, (45.02±5.83)% in 400 nmol/L crizotinib treatment group and (17.43±3.83)% in combined treatment group. Silibinin combined with crizotinib treatment significantly inhibited the colony formation ability of H2228 and H3122 cells (P<0.01). Migration and invasion results showed that combined treatment of crizotinib and silibinin markedly inhibited the migration and invasion ability of H2228 cells (P<0.01). Western blot results indicated that treated with silibinin alone or in combination of crozitinib for 48 hours, the protein level of E-cadherin in H2228 cells was upregulated, while the expressions of p-ALK and vimentin were downregulated, without obvious alteration of ALK protein expression. In the xenograft model, the mean tumor weight was (9.40±2.58)g in crizotinib treatment group and (4.58±1.07)g in the combined treatment group. The inhibitory effect of tumor growth in vivo of combined treatment was significantly superior to that of crizotinib treatment alone (P<0.05). Conclusion: Silibinin enhances the inhibitory effect of crizotinib on ALK positive NSCLC cells, which may be associated with suppression of ALK activity and mesenchymal-epithelial transition. 目的: 研究水飞蓟宾联合克唑替尼对间变性淋巴瘤激酶(ALK)基因阳性非小细胞肺癌(NSCLC)细胞的增殖抑制作用和机制。 方法: 采用单加水飞蓟宾、单加克唑替尼或两药联合作用于NSCLC细胞株H2228和H3122,以四甲基偶氮唑蓝(MTT)法和克隆形成实验检测细胞的增殖活性,以划痕实验和侵袭实验检测细胞的迁移和侵袭能力,以免疫荧光实验检测细胞上皮间质转化(EMT)标志蛋白E-Cadherin和Vimentin的表达情况,以Western blot法检测细胞中ALK、p-ALK、E-Cadherin和Vimentin蛋白的表达变化。将H2228细胞悬液注射入裸鼠皮下,构建裸鼠移植瘤模型,观察移植瘤的生长情况。 结果: MTT法检测结果显示,当水飞蓟宾浓度为100 μmol/L时,H2228和H3122细胞的存活率分别为(88.38±4.10)%和(72.27±3.62)%,对细胞的增殖活性影响较小。当100 μmol/L的水飞蓟宾与克唑替尼联合使用时,克唑替尼对H2228细胞的IC(50)从(917.10±7.75)nmol/L下降到(238.73±7.67)nmol/L,对H3122细胞的IC(50)从(472.50±15.70)nmol/L下降到(206.10±12.01)nmol/L,联合用药后克唑替尼对H2228和H3122细胞的IC(50)明显降低。与对照组H2228细胞比较,100 μmol/L水飞蓟宾组、400 nmol/L克唑替尼组、100 μmol/L水飞蓟宾联合400 nmol/L克唑替尼组H2228细胞的克隆形成率分别为(83.34±2.72)%、(69.42±3.06)%和(27.32±1.42)%;与对照组H3122细胞比较,100 μmol/L水飞蓟宾组、400 nmol/L克唑替尼组、100 μmol/L水飞蓟宾联合400 nmol/L克唑替尼组H2228细胞的克隆形成率分别为(84.45±5.67)%、(45.02±5.83)%和(17.43±3.83)%。水飞蓟宾联合克唑替尼后,H2228和H3122细胞的克隆形成能力均明显下降(均P<0.01)。迁移和侵袭实验结果显示,水飞蓟宾与克唑替尼联用能明显抑制H2228细胞的迁移和侵袭(均P<0.01)。Western blot法检测结果显示,无论单用水飞蓟宾、还是联合克唑替尼,H2228细胞中E-Cadherin蛋白的表达明显升高,p-ALK、Vimentin蛋白表达明显下降,ALK总蛋白的表达无明显变化。单用克唑替尼组和联合用药组的肿瘤重量分别为(9.40±2.58)g和(4.58±1.07)g,联合用药组的抑瘤效果明显好于克唑替尼单药组(P<0.05)。 结论: 水飞蓟宾可增强克唑替尼对ALK阳性NSCLC细胞的增殖抑制作用,其机制可能与两药联用能进一步降低ALK阳性NSCLC细胞的ALK活性,促进间质上皮转化(MET)的发生有关。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Lin CC, Lu CH, Pan YH, et al. [Effect and mechanism of silibinin on the inhibition of ALK positive NSCLC cells by sensitizing crizotinib]. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 28926892. doi:10.3760/cma.j.issn.0253-3766.2017.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。